The use of this massive genetic sequencing platform could improve patient survival thanks to the detection of therapeutic targets and mutations that predispose to cancer.
A study led by Dr. Sara Larriba’s team at IDIBELL, in collaboration with Fundació Puigvert and IGTP, demonstrates that the concentration of microRNAs and their isoforms in semen samples may reflect alterations in sperm production.
Researchers from IDIBELL and ICO have used computational models to analyze bone marrow transplant data from 33,927 patients and develop a tool that provides personalized estimates of mortality from this type of therapies.
Artificial intelligence helps take decisions about bone marrow transplant Read More »
A team of international researchers has identified the specific processes by which the MYC oncogene promotes this disease and, this way, demonstrated that this gene can attack specific weaknesses in tumor cells.
Scientists open up a new way to fight cancer through the MYC gene Read More »
The research group has managed to demonstrate the good results of an algorithm that adjusts the doses of the immunosuppressant tacrolimus according to the characteristics of each person. The results have been published in the scientific journal Kidney International.
The model has been created by injecting tumor cells from a patient into a mouse to mimic the transformation of leukemia into a more aggressive form, making it possible to learn about the real evolution of the disease and be able to test new treatments.
In November, Bonpreu and Esclat clients made 185.804 donations that have made it possible to obtain 25.907€ for IDIBELL to develop new therapies for diabetes through the Solidarity Roundup, a tool developed by Worldcoo.
IDIBELL receives 25.907€ thanks to the donations of Bonpreu and Esclat customers Read More »
The World’s Top 2% Scientists ranking is published every year by Stanford University and lists around 180.000 researchers from 22 scientific fields.
30 IDIBELL researchers among the most cited scientists in the world Read More »
The three finalists have been selected from around thirty projects from Catalan hospitals or healthcare innovation centres. The prize is worth 15,000 euros and has the collaboration of IDIBELL-XarSMART.
An IDIBELL project is a finalist in the VTSO Health Innovation Award Read More »
On November 27 and 28, the first edition of the RegenBell symposium on stem cells and regenerative medicine took place, organized by IDIBELL’s Regenerative Medicine Program (RegenBell). The event was attended by more than 165 people.
The first RegenBell symposium on stem cells and regenerative medicine takes place Read More »
